Established in Edinburgh, UK, in 2006, Roslin Cells has spent the last decade developing into a leader in the “development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).” With major facilities in both Edinburgh and Cambridge, the company can produce large volumes of cell lines from different donors, allowing pharmaceutical researchers to assess how drug performance can differ from individual to individual.
On January 11th, 2016, Roslin Cells announced major news that it is creating two subsidiary companies, one to facilitate “process development and manufacture of cell therapies for clinical trials” and the other to “focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.” This will strengthen Roslin Cell’s position as a leader in both clinical-grade cell manufacturing and in iPSC production for drug discovery applications.
To learn more, view the full press release, published below with permission from Daria Olijnyk-Dallis, Business Development Executive for Roslin Cell Therapies.
Roslin Cells announces the creation of two commercially focused subsidiaries: Roslin Cell Therapies and Roslin Cell Sciences
PRESS RELEASE; Edinburgh, Scotland, 11th January 2016 — Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations. Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials. Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.
Roslin Cell Therapies
Roslin Cell Therapies builds on the wealth of expertise and industry recognition developed by Roslin Cells in the process development and manufacture of Cell Therapies and Advanced Therapy Medicinal Products (ATMPs). Based at Edinburgh BioQuarter, where it operates purpose built clean room facilities, the company will continue to provide contract manufacturing services for clinical trial supply.
Roslin Cell Sciences
Roslin Cell Sciences will focus on further development of Roslin Cells’ expertise in the creation of induced Pluripotent Stem Cells (iPSCs) for commercial and academic drug research. There is an increasing appreciation that iPSCs offer a wholly new means of evaluating new drugs and their suitability for particular patients. With facilities in both Edinburgh and Cambridge, UK, the company is capable of creating large numbers of iPS cell lines from cohorts of donors. Creating cell lines in this way will enable researchers to understand better how drug performance varies between individuals due to their genetic variation.
Aidan Courtney, Chief Executive Officer stated “Since we founded the company in 2006, it has developed two distinct businesses both operating in rapidly developing markets – the manufacture of cell therapies and the use of iPSCs for research. By creating two separate commercial entities, we will be best placed to maximise the growth and success of both.”
Press Contacts
Roslin Cell Therapies
Dr Daria Olijnyk-Dallis, Business Development Executive
Tel: +44 (0)131 658 5180; Mobile: +44 (0)7867494071
Email: daria.olijnyk-dallis@roslincells.com; Web: www.roslincells.com/roslincelltherapies
Roslin Cell Sciences
Kevin Bruce, Head of Commercial
Tel: +44 (0)131 440 6543; Mobile: +44 (0)7825 393 287
Email: kevin.bruce@roslincs.com; Web: www.roslincells.com/roslincellsciences
Want to be better informed than your competition? Get future stem cell industry updates.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.
Tell Us What You Think!